SUPN

#1833
Supernus Pharmaceuticals, Inc. - Common Stock
44.0 3 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
44.03
44.03
Jahresspanne
42.45
59.68
Tagesänderung
+0.66%
Monatliche Änderung
-4.76%
6 month change
-19.54%
Jahresänderung
-18.46%
Vorheriger Schlusskurs
43.7 4
Open
44.0 3
Tief
44.0 3
Hoch
44.0 3
Volumen
84
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 29 August 2018

Full document

Business Context and Reporting Period

Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 29, 2018
Reporting Period: This filing provides a status update on clinical trial progress and corporate events as of August 29, 2018, rather than a financial reporting period.

Key Financial Metrics

This Form 8-K filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on clinical development updates and regulatory disclosures.

Material Changes and Clinical Progress

SPN-812 (ADHD) Phase III Studies

  • Enrollment Status: Enrollment is complete for studies P301, P302, and P303. Enrollment for study P304 is approximately 76% complete.
  • Data Expectations: Data for P301, P302, and P303 is expected in the fourth quarter of 2018. Data for P304 is expected in the first quarter of 2019.
  • Study Details:
    • P301: 432 patients (ages 6-11), 100-200mg dose.
    • P302: 300 patients (ages 6-11), 200-400mg dose.
    • P303: 300 patients (ages 12-17), 200-400mg dose.
    • P304: 234 patients (ages 12-17), 400-600mg dose.
  • Open Label Extension: Rollover from Phase III trials remains at approximately 90%.

Bipolar Program Update

  • Phase III Plans: The Company plans to initiate the pivotal Phase III bipolar program in the second half of 2019.
  • Strategic Shift: Following market research and claims database analysis on oxcarbazepine in bipolar, the Company stopped the investigator-initiated trial on Oxtellar XR in bipolar, deeming it no longer necessary.

Guidance, Outlook, and Risks

  • Forward-Looking Statements: The filing contains predictions regarding data release dates (4Q 2018 and 1Q 2019) and program initiation (2H 2019). These are subject to risks and uncertainties.
  • Corporate Events: Management will present an overview and host investor meetings at the 2018 Wells Fargo Healthcare Conference in Boston, MA, on September 5, 2018.
  • Risk Factors: The filing references risk factors detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

Investor Verification Checklist

  • Verify the final enrollment numbers for study P304 once the remaining 24% is completed.
  • Monitor the actual data release dates for studies P301, P302, and P303 in 4Q 2018 against the current expectation.
  • Review the finalized design and timeline for the pivotal Phase III bipolar program scheduled for initiation in 2H 2019.
  • Attend or review the transcript of the presentation at the 2018 Wells Fargo Healthcare Conference on September 5, 2018, for further management commentary.

Nachrichten